# Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration

> **NCT02707458** · PHASE1,PHASE2 · COMPLETED · sponsor: **Douglas Mental Health University Institute** · enrollment: 23 (actual)

## Conditions studied

- Dementia of the Alzheimer Type
- Age-related Cognitive Decline
- Mild Cognitive Impairment Due to Alzheimer Disease

## Interventions

- **DRUG:** Probucol

## Key facts

- **NCT ID:** NCT02707458
- **Lead sponsor:** Douglas Mental Health University Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707458, "Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02707458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*